Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study
Open Access
- 9 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 64 (6), 1235-1245
- https://doi.org/10.1007/s00125-021-05393-8
Abstract
Aims/hypothesis: Type 2 diabetes, particularly with concomitant CVD, is associated with an increased risk of cognitive impairment. We assessed the effect on accelerated cognitive decline (ACD) of the DPP-4 inhibitor linagliptin vs the sulfonylurea glimepiride in individuals with type 2 diabetes. Methods: The CAROLINA-COGNITION study was part of the randomised, double-blind, active-controlled CAROLINA trial that evaluated the cardiovascular safety of linagliptin vs glimepiride in individuals with age ≥40 and ≤85 years and HbA1c 48–69 mmol/mol (6.5–8.5%) receiving standard care, excluding insulin therapy. Participants were randomised 1:1 using an interactive telephone- and web-based system and treatment assignment was determined by a computer-generated random sequence with stratification by center. The primary cognitive outcome was occurrence of ACD at end of follow-up, defined as a regression-based index score ≤16th percentile on either the Mini-Mental State Examination (MMSE) or a composite measure of attention and executive functioning, in participants with a baseline MMSE score ≥24. Prespecified additional analyses included effects on ACD at week 160, in subgroups (sex, age, race, ethnicity, depressive symptoms, cardiovascular risk, duration of type 2 diabetes, albuminuria), and absolute changes in cognitive performance. Participants, caregivers, and people involved in measurements, examinations or adjudication, were all masked to treatment assignment. Results: Of 6033 participants recruited from hospital and primary care sites, 3163 (38.0% female, mean age/diabetes duration 64/7.6 years, MMSE score 28.5, HbA1c 54 mmol/mol [7.1%]) represent the CAROLINA-COGNITION cohort. Over median 6.1 years, ACD occurred in 27.8% (449/1618, linagliptin) vs 27.6% (426/1545, glimepiride), OR 1.01 (95% CI 0.86, 1.18). Also, no differences in ACD were observed at week 160 (OR 1.07 [0.91, 1.25]), between treatments across subgroups, or for absolute cognitive changes. Conclusions/interpretation: In a large, international outcome trial in people with relatively early type 2 diabetes at elevated cardiovascular risk, no difference in risk for ACD was observed between linagliptin and glimepiride over 6.1 years. Funding: This study was sponsored by Boehringer Ingelheim. Trial registration: ClinicalTrials.gov NCT01243424. GraphicalFunding Information
- Boehringer Ingelheim
This publication has 36 references indexed in Scilit:
- Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventionsThe Lancet Diabetes & Endocrinology, 2014
- Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With MetforminDiabetes Care, 2013
- Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort studyThe Lancet Diabetes & Endocrinology, 2013
- Glucose Levels and Risk of DementiaThe New England Journal of Medicine, 2013
- DPP-4 Inhibition and Neuroprotection: Do Mechanisms Matter?Diabetes, 2013
- Metformin, Other Antidiabetic Drugs, and Risk of Alzheimer's Disease: A Population-Based Case-Control Study2012
- Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trialDiabetologia, 2009
- Relationships between Parts A and B of the Trail Making TestJournal of Clinical Psychology, 1987
- The CES-D ScaleApplied Psychological Measurement, 1977
- “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinicianJournal of Psychiatric Research, 1975